An Open-label Prospective Trial to Evaluate the Tolerability, Safety and Maintained Efficacy of a Transition to Paliperidone ER in Subjects With Schizophrenia Previously Unsuccessfully Treated With Other Oral Antipsychotics
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms INSTAR
- Sponsors Johnson & Johnson
- 05 Aug 2009 Actual patient number (299) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from not yet recruiting to completedas reported by ClinicalTrials.gov.
- 05 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.